Document is current
Any future updates will be listed below
-
Authors
Park, Hyunji
Cheon, Jiwon
Kim, Hyojung
kim, Jihye
Kim, Jihyun https://orcid.org/0009-0009-6855-5014
Shin, Jeong-Yong
Kim, Hyojin
Ryu, Gaeun
Chung, In Young
Kim, Ji Hun
Kim, Doeun
Zhang, Zhidong
Wu, Hao https://orcid.org/0000-0003-1314-4954
Beck, Katharina R.
Bäckhed, Fredrik
Kim, Han-Joon https://orcid.org/0000-0001-8219-9663
Lee, Yunjong https://orcid.org/0000-0003-0182-2279
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2023R1A2C1002876, RS-2024-00361688, RS-2024-00349023)
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 19 August 2025
First Online: 5 September 2025
Competing interests
: F.B. is a co-founder of Implexion Pharma AB and Roxbiosens Inc., receives research funding from Biogaia AB and is on the scientific advisory board of Bactolife A/S. A.K. and K.R.B. are a shareholder of Implexion Pharma AB. The remaining authors declare no competing interests.
